Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
jin-3
- Development stage
- Preclinical
- Lead developer
- Leiden University Medical Center
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
jin-3 is a bioselected oncolytic reovirus mutant derived from the Mammalian Orthoreovirus type 3 Dearing (T3D) strain. It was specifically developed to overcome the requirement for the Junction Adhesion Molecule-A (JAM-A) receptor, which is the primary entry receptor for wild-type reoviruses but is frequently downregulated in advanced or aggressive tumors. By utilizing a JAM-A-independent entry mechanism, jin-3 exhibits expanded tropism, allowing it to infect and replicate in a broader range of cancer cells. The virus functions through direct oncolysis—lytic replication that destroys tumor cells—and by stimulating the host immune system. This stimulation occurs via the induction of immunogenic cell death (ICD), which triggers the expression of interferon-stimulated genes (ISGs) and the release of inflammatory cytokines, potentially converting immunologically "cold" tumors into "hot" tumors. Preclinical studies have demonstrated its efficacy in multiple human prostate cancer models, including castration-resistant prostate cancer (CRPC) and patient-derived xenografts.
- Other names
- reovirus mutant jin-3bioselected oncolytic reovirus mutant jin-3
02
Targets
SA (Sialic acid)
Beyond the preview
Go deeper on jin-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on jin-3.